An exploratory Phase IIA clinical study of ORY-1001 in combination with other agents in patients with Acute myeloid leukaemia
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2018
At a glance
- Drugs RG 6016 (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 30 Jul 2018 According to an Oryzon media release, the company has filed the corresponding CTA authorizations to Regulatory Agencies to carry out this trial, and will inform about its regulatory approval and the operational start thereof in due time.
- 05 Mar 2018 According to an Oryzon media release, the company is planning to start this trial in 2H 2018.
- 21 Feb 2018 New trial record